Literature DB >> 23825362

Vav Guanine nucleotide exchange factors regulate atherosclerotic lesion development in mice.

Shaik O Rahaman1, Wei Li, Roy L Silverstein.   

Abstract

OBJECTIVE: Atherosclerosis requires migration of monocytes to the arterial intima, with subsequent differentiation into foam cells. We showed previously that the scavenger receptor CD36 contributes to the activation of Vav family guanine nucleotide exchange factors (Vavs) in aortae from hyperlipidemic apoE-null mice and that oxidatively modified low-density lipoprotein induced CD36-dependent activation of macrophage Vavs in vitro. We also discovered that CD36-dependent uptake of oxidized low-density lipoprotein and foam cell formation were reduced in Vav-deficient macrophages. We now tested the hypothesis that Vavs play a role in atherosclerotic lesion development. APPROACH AND
RESULTS: We showed that apoE/vav1 double-null mice fed a Western diet had significant reduction in total aortic lesion area (by en face analysis) compared with apoE-null mice, with no significant differences in body weight or plasma lipid profiles. Histological analysis of aortic sinus lesions showed fewer macrophages and foam cells in double-null mice compared with apoE-null mice, indicating impaired foam cell generation and homing of macrophages to atherosclerotic lesions. An intravital video microscopy-based adhesion assay with fluorescent (Qtracker655)-labeled monocytes showed reduced adhesion of vav1-null monocytes to hyperlipidemic carotid arteries compared with wild-type monocytes. Furthermore, fewer fluorescently labeled vav1-null monocytes accumulated in aortic sinus lesions in hyperlipidemic apoE-null mice. We also found that activation of RhoGTPase Rac and mitogen-activated protein kinase c-Jun N-terminal kinase-2 by CD36-specific oxidized phospholipids was dependent on Vavs.
CONCLUSIONS: These results for the first time link Vavs to atherosclerotic lesion development and suggest that Vavs act as critical molecular links coupling hyperlipidemia with proatherogenic monocyte/macrophage responses.

Entities:  

Keywords:  CD36; Vav family guanine nucleotide exchange factors; atherosclerosis; foam cells; macrophages

Mesh:

Substances:

Year:  2013        PMID: 23825362      PMCID: PMC3864095          DOI: 10.1161/ATVBAHA.113.301414

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  31 in total

1.  Control of lymphocyte shape and the chemotactic response by the GTP exchange factor Vav.

Authors:  Miguel Vicente-Manzanares; Aranzazu Cruz-Adalia; Noa B Martín-Cófreces; José R Cabrero; Mercedes Dosil; Brenda Alvarado-Sánchez; Xosé R Bustelo; Francisco Sánchez-Madrid
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

2.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

Authors:  M Febbraio; E A Podrez; J D Smith; D P Hajjar; S L Hazen; H F Hoff; K Sharma; R L Silverstein
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway.

Authors:  O A Coso; M Chiariello; J C Yu; H Teramoto; P Crespo; N Xu; T Miki; J S Gutkind
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

4.  Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.

Authors:  P Crespo; X R Bustelo; D S Aaronson; O A Coso; M Lopez-Barahona; M Barbacid; J S Gutkind
Journal:  Oncogene       Date:  1996-08-01       Impact factor: 9.867

Review 5.  Vav-family proteins in T-cell signalling.

Authors:  Victor L J Tybulewicz
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

6.  Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis.

Authors:  Romeo Ricci; Grzegorz Sumara; Izabela Sumara; Izabela Rozenberg; Michael Kurrer; Alexander Akhmedov; Martin Hersberger; Urs Eriksson; Franz R Eberli; Burkhard Becher; Jan Borén; Mian Chen; Myron I Cybulsky; Kathryn J Moore; Mason W Freeman; Erwin F Wagner; Christian M Matter; Thomas F Lüscher
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

7.  Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner.

Authors:  Zhenze Zhao; Maria C de Beer; Lei Cai; Reto Asmis; Frederick C de Beer; Willem J S de Villiers; Deneys R van der Westhuyzen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-28       Impact factor: 8.311

Review 8.  Vav1: an oncogene that regulates specific transcriptional activation of T cells.

Authors:  Shulamit Katzav
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

9.  A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Maria Febbraio; David P Hajjar; Roy L Silverstein; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

10.  Vav GEFs are required for beta2 integrin-dependent functions of neutrophils.

Authors:  M Angelica Martinez Gakidis; Xavier Cullere; Timothy Olson; Julie L Wilsbacher; Bin Zhang; Sheri L Moores; Klaus Ley; Wojciech Swat; Tanya Mayadas; Joan S Brugge
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  15 in total

Review 1.  Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis.

Authors:  Sasha A Doodnauth; Sergio Grinstein; Michelle E Maxson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 2.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

3.  The three members of the Vav family proteins form complexes that concur to foam cell formation and atherosclerosis.

Authors:  Rong Huang; Guo Guo; Liaoxun Lu; Rui Fu; Jing Luo; Zhuangzhuang Liu; Yanrong Gu; Wenyi Yang; Qianqian Zheng; Tianzhu Chao; Le He; Ying Wang; Zhiguo Niu; Hui Wang; Toby Lawrence; Marie Malissen; Bernard Malissen; Yinming Liang; Lichen Zhang
Journal:  J Lipid Res       Date:  2019-09-30       Impact factor: 5.922

4.  Oxidized LDL-bound CD36 recruits an Na⁺/K⁺-ATPase-Lyn complex in macrophages that promotes atherosclerosis.

Authors:  Yiliang Chen; David J Kennedy; Devi Prasadh Ramakrishnan; Moua Yang; Wenxin Huang; Zhichuan Li; Zijian Xie; Alexandra C Chadwick; Daisy Sahoo; Roy L Silverstein
Journal:  Sci Signal       Date:  2015-09-08       Impact factor: 8.192

5.  Ferric Chloride-induced Murine Thrombosis Models.

Authors:  Wei Li; Marvin Nieman; Anirban Sen Gupta
Journal:  J Vis Exp       Date:  2016-09-05       Impact factor: 1.355

Review 6.  Lipoprotein receptor signalling in atherosclerosis.

Authors:  Chieko Mineo
Journal:  Cardiovasc Res       Date:  2020-06-01       Impact factor: 10.787

7.  Mechanotransduction via a TRPV4-Rac1 signaling axis plays a role in multinucleated giant cell formation.

Authors:  Rakesh K Arya; Rishov Goswami; Shaik O Rahaman
Journal:  J Biol Chem       Date:  2020-12-04       Impact factor: 5.157

Review 8.  CD36 signaling in vascular redox stress.

Authors:  Moua Yang; Roy L Silverstein
Journal:  Free Radic Biol Med       Date:  2019-02-27       Impact factor: 8.101

Review 9.  CD36, a scavenger receptor implicated in atherosclerosis.

Authors:  Young Mi Park
Journal:  Exp Mol Med       Date:  2014-06-06       Impact factor: 8.718

10.  Nε-Carboxymethyl-Lysine Negatively Regulates Foam Cell Migration via the Vav1/Rac1 Pathway.

Authors:  Zhengyang Bao; Lili Zhang; Lihua Li; Jinchuan Yan; Qiwen Pang; Zhen Sun; Yue Geng; Lele Jing; Chen Shao; Zhongqun Wang
Journal:  J Immunol Res       Date:  2020-02-28       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.